#newborn screening market scope

[soumyafwr]

https://kyourc.com/read-blog/32279_newborn-screening-market-analysis-size-share-and-forecast-2031.html

Newborn Screening Market Analysis, Size, Share, and Forecast 2031

[blogaarti]

Newborn Screening Market Analysis, Market Size, In-Depth Insights, Growth and Forecast 2029

The newborn screening test helps in diagnosing rare diseases in newborns, facilitating early treatment. A steady rise in birth rate coupled with rising incidence of serious health disorders among newborns has amplified the demand for newborn screening around the world. Introduction of favourable government programs & legislations is contributing to the demand for newborn screening. Rise in disposable income and provided affordability is making newborn screening more accessible. These aspects, coupled with cutting-edge developments in the health screening domain have propelled significant growth across the global newbron screening market. Besides, parents have become more conscious of the health of their infants further accelerating the pace of market expansion. All these trends hint at the presence of lucrative business possibilities in the global newborn screening market, over the forecast period.  

 For More Industry Insight Read: https://www.fairfieldmarketresearch.com/report/newborn-screening-market

 An Upswing in Health Disorders to Facilitate Newborn Screening Market Expansion

As people are becoming more informed of the health benefits associated with newborn screening, the demand has also mounted at a significant rate. Some of the most prominent newborn screening tests include tests for metabolic disorders, haemoglobin (red blood cell) conditions, hormone (endocrine) disorders, and immune system disorders. Besides, other rare conditions such as Pompe disease, cystic fibrosis, spinal muscular atrophy and X-linked adrenoleukodystrophy are also being significantly diagnosed. An incessant rise in such serious health conditions among infants is creating substantial demand for newborn screening at a global level. Uptick in demand and prevailing serious health disorders are likely to place newborn screening market on a sound growth trajectory.  

 Growing Incidence of Congenital Heart Abnormalities to Create Significant Growth Prospects for Newborn Screening Market

The rising cases of congenital heart abnormalities including tricuspid atresia and pulmonary atresia globally are driving the newborn screening market. Critical congenital heart defects are the most serious congenital heart defects and newborns with critical CHDs require surgery or other treatment within the first year of their life. Therefore, healthcare experts are advocating and supporting the need for more sophisticated screening tools. Furthermore, medical advancements that include ongoing drug discovery, government and non-government organisational initiatives have promoted awareness regarding congenital heart abnormalities. Considering these factors, the global newborn screening market is set to register fruitful outcomes in revenue generation and business expansion.

 North America to Emerge as Key Region Owing to Favourable Reimbursement Policies

The growing prevalence of congenital disorders and mandatory testing in all states are key factors cementing North America as a key revenue generator in the global newborn screening market. In addition to this, the advancements in healthcare infrastructure are projected to bode well for the market. Other factors boosting the growth of the regional market include favourable reimbursement policies and the available newborn screening programs. The cumulative force of these factors is projected to unlock new revenue opportunities for the newborn screening market in North America.

 Leading Market Players

Some of the global players in the newborn screening market include Trivitron Healthcare (India), PerkinElmer (US), Natus Medical (US), Danaher Corporation (US), Demant A/S (Denmark), Bio-Rad Laboratories (US), Chromsystems Instruments & Chemicals GmbH (Germany), and Baebies (US), Medtronic (Ireland), and Recipe Chemicals+Instruments (Germany).

 For More Information Visit: https://www.fairfieldmarketresearch.com/report/newborn-screening-market

 About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[insightfulblogz]

Spinal Muscular Atrophy Treatment Market Value, Region, and Forecast to 2032

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and loss of motor function. It primarily occurs in infants and children, with varying degrees of severity. Until recently, treatment options for SMA were limited to supportive care. However, groundbreaking therapies have emerged in recent years, offering new hope for those affected by the condition. These include gene therapy, antisense oligonucleotide treatments, and small molecule drugs that target the underlying genetic cause of the disease, significantly improving survival rates and motor function.

The Spinal Muscular Atrophy Treatment Market size was estimated at USD 4.48 billion in 2023 and is expected to reach USD 8.16 billion by 2032 at a CAGR of 6.9% during the forecast period of 2024-2032.

Future Scope

The future of Spinal Muscular Atrophy treatment is centered on refining and expanding the current therapeutic options. Gene therapy, which targets the root cause of SMA by replacing the faulty SMN1 gene, is expected to evolve with more targeted delivery mechanisms and potentially lower costs, making it accessible to a broader patient population. Research is also underway to develop combination therapies that address both the genetic and symptomatic aspects of the disease, further improving patient outcomes. Additionally, early diagnosis through newborn screening programs will enable timely intervention, preventing irreversible damage and enhancing the effectiveness of treatment.

Trends

One of the major trends in SMA treatment is the development of disease-modifying therapies that target the genetic cause of the disorder. These include gene replacement therapies like Zolgensma, which introduces a functional copy of the SMN1 gene, and antisense therapies like Spinraza, which helps produce more of the necessary SMN protein. Another emerging trend is the focus on combination therapies that use both genetic treatments and medications to address muscle atrophy and weakness. Furthermore, the push for early diagnosis and newborn screening programs is gaining momentum, allowing for earlier intervention and better long-term outcomes.

Applications

SMA treatments are primarily used to address the genetic and symptomatic aspects of the disease. Gene therapy, such as Zolgensma, directly replaces the faulty gene responsible for SMA, offering a one-time treatment that has shown significant improvements in motor function. Antisense oligonucleotide therapies, like Spinraza, are administered through regular spinal injections to enhance the production of the survival motor neuron (SMN) protein, slowing disease progression. Small molecule drugs, like Evrysdi, are taken orally to increase SMN protein levels. These therapies offer a range of treatment options depending on the patient's age, disease severity, and overall health.

Key Points

Spinal Muscular Atrophy is a genetic disorder that causes muscle weakness and motor function loss.

Recent advances in gene therapy, antisense treatments, and small molecule drugs offer new hope for SMA patients.

Gene replacement therapy, such as Zolgensma, targets the underlying genetic cause of the disease.

Antisense therapies like Spinraza help produce more SMN protein, slowing disease progression.

Early diagnosis through newborn screening is crucial for timely intervention and improved outcomes.

Conclusion

Spinal Muscular Atrophy treatment has made significant strides in recent years, offering new possibilities for patients through gene therapy, antisense treatments, and small molecule drugs. As research continues to push the boundaries of what is possible, the future of SMA treatment will likely involve more refined and accessible therapies, early diagnosis, and improved long-term outcomes for patients. With continued innovation, SMA patients can look forward to better quality of life and enhanced treatment options.

Read More Details: https://www.snsinsider.com/reports/spinal-muscular-atrophy-treatment-market-3384 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[severepeanutperfection]

Newborn Metabolic Screening Market Demand, Scope and Future Estimation until 2032

The Newborn Metabolic Screening Market plays a pivotal role in early disease detection and intervention for newborns, making it an essential component of public health programs worldwide. Newborn metabolic screening, also known as newborn screening or heel prick testing, involves the collection of a small blood sample from a baby's heel shortly after birth to screen for a variety of congenital and metabolic disorders. The market for this screening has experienced steady growth due to the increasing awareness of the benefits of early diagnosis and advancements in testing technologies.

One of the primary drivers of the Newborn Metabolic Screening Market is the growing recognition of the importance of early disease detection in infants. Timely identification of metabolic and genetic disorders allows for prompt intervention and treatment, often preventing serious health complications or even fatalities. As healthcare systems emphasize the value of preventative care, newborn screening programs have expanded, contributing to the market's growth.

Advancements in screening technologies have significantly improved the accuracy and efficiency of newborn metabolic screening. The development of tandem mass spectrometry (TMS) and next-generation sequencing (NGS) techniques has allowed for the simultaneous testing of multiple disorders from a single blood sample. These technological innovations have not only enhanced the scope of screening but have also made it more cost-effective, encouraging its adoption in healthcare systems around the world.

Additionally, international initiatives and guidelines have played a crucial role in standardizing newborn metabolic screening practices. Organizations such as the World Health Organization (WHO) and the American College of Medical Genetics and Genomics (ACMG) have provided recommendations and guidelines for expanding newborn screening panels and ensuring uniform screening practices. This standardization has facilitated the market's growth by promoting consistency and reliability in testing methodologies.

For More Info@ https://www.openpr.com/news/2679096/newborn-metabolic-screening-market-to-grow-backed-by-5g-at-a-cagr

Despite its growth, challenges persist in the Newborn Metabolic Screening Market, including the need for ongoing education and awareness among healthcare providers, parents, and caregivers. Furthermore, access to screening programs and follow-up care can vary significantly from one region to another, highlighting the importance of equity in healthcare. Nevertheless, the Newborn Metabolic Screening Market is expected to continue growing as advances in technology and increased awareness drive the expansion of newborn screening programs globally, ultimately improving the health outcomes of infants.

[shital1998]

Genetic Testing Market – Global Opportunity Analysis and Industry Forecast (2022-2029)

Meticulous Research®—a leading global market research company, published a research report titled, ‘Genetic Testing Market By Product (Consumables, Reagents, Instruments, Services), Test Type (Diagnostic, Prenatal, Carrier, Newborn, Preimplantation), Method (Molecular, Chromosomal), End User (Hospitals, Diagnostic Laboratories) - Global Forecast to 2029.’

According to this latest publication from Meticulous Research®, the genetic testing market is expected to grow at a CAGR of 11.6% from 2022 to reach $43.3 billion by 2029. The growth of this market is attributed to factors such as favorable government initiatives for promoting genetic testing, increasing prevalence of genetic disorders, increased need for early disease detection & prevention, increasing applications of genetic testing in oncology, and decreasing cost of sequencing procedures. In addition, the growing scenario of genetic direct-to-consumer genetic testing and the emerging field of genetic counseling is expected to provide significant growth opportunities for this market.

However, factors such as the high cost of genetic testing and the social and ethical implications of genetic testing are restraining the growth of this market to a notable extent. In addition, factors such as low chances of positive, actionable mutations and genetic data privacy & security concerns are the major challenges to the growth of this market.

Genetic Testing Market: Future Outlook

The genetic testing market is segmented based on product, test type, method, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Download Research Sample https://www.meticulousresearch.com/download-sample-report/cp_id=5370

Scope of the Report:

Genetic Testing Market, by Product & Service

·         Consumables & Reagents

·         Instruments

·         Services

Genetic Testing Market, by Test Type

·         Diagnostic Testing

·         Prenatal Testing

·         Carrier Testing

·         Newborn Screening

·         Preimplantation Testing

·         Other Test Types (Other test types include forensic testing, microorganism genomics, and posthumous (testing of post-mortem tissues etc.)

Genetic Testing Market, by Method

·         Molecular Tests

·         Chromosomal Tests

·         Biochemical Tests

Genetic Testing Market, by End User

·         Hospitals & Clinics

·         Diagnostic Laboratories

·         Academic & Research Institutes

·         Others End Users (Other end users include contract research organizations, forensic laboratories, pharma & biotech companies, government laboratories, etc.)

Genetic Testing Market, by Geography

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    France

o    U.K.

o    Italy

o    Spain

o    Rest of Europe (RoE)

·         Asia-Pacific

o    China

o    Japan

o    India

o    Rest of APAC (RoAPAC)

·         Latin America

·         Middle East & Africa

Speak with Our Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5370

Based on product, in 2022, the consumables & reagents segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the recurrent use of reagents & consumables, availability of a wide range of genetic tests, recent product launches, and increased awareness about the advantages of genetic testing.

Based on test type, in 2022, the diagnostic testing segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the high prevalence of chronic diseases such as cancer, technological advancements in genomic-based diagnostic testing, and the demand for early disease diagnosis.

Based on method, in 2022, the molecular segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the ability to detect the mutation at single nucleotide resolution with cheaper, faster, and with the utmost accuracy by using whole genome sequencing (WGS) and whole exome sequencing (WES) technology.

In 2022, based on end user, the hospitals & clinics segment is estimated to account for the largest share of the market. The large share of this segment is attributed to the high volume of genetic tests performed in hospitals & clinics and the high demand for early disease diagnosis and treatment.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and the Middle East & Africa.

In 2022, North America is estimated to account for the largest share of the genetic testing market, followed by Europe and Asia-Pacific. North America’s large market share is attributed to the factors such as high healthcare expenditure, favorable reimbursement scenario, high awareness among patients about genetic testing, and increased support and investments to enhance genome sequencing infrastructure in the region.

Access full Report Description, TOC, Table of Figure, Chart, etc: https://www.meticulousresearch.com/product/genetic-testing-market-5370

Key Players

The key players operating in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), 23andMe, Inc. (U.S.), Foundation Medicine, Inc. (U.S.) (Subsidiary of Roche Holding AG), Rosetta Genomics Ltd. (U.S.), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.) and Invitae Corporation (U.S.).

Key questions answered in the report-

·  Which are the high-growth market segments in terms of product, test type, method, end user, and region/country?

·  What was the historical market size for genetic testing across the globe?

·  What are the market forecasts and estimates for the period 2022–2029?

·  What are the major drivers, restraints, opportunities, and challenges in the global genetic testing market?

·  Who are the major players in the genetic testing market?

·  How is the competitive landscape, and who are the market leaders in the global genetic testing market?

·  What are the recent developments in the global genetic testing market?

·  What are the different strategies adopted by the major players in the global genetic testing market?

·  What are the geographical trends and high-growth regions/countries?  

Contact Us:

Meticulous Research

®

Email- 

sales@meticulousresearch.com

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn- 

https://www.linkedin.com/company/meticulous-research

[vynzresearchindia]

Global Newborn Screening Market Size, Share and Demand Forecast Report by 2027 | VynZ Research

The Global Newborn Screening Market was value at US$ 0.85 billion in 2020 and it is expected to grow with a strong CAGR of 7.8% during the 2021-2027. In order to achieve the targeted revenue, the market report employs significant and insightful statistics of historical and forecasted data based on growth drivers, challenges and restraints. The report also evaluates the opportunities including technical and government supports for the entrants to joins the market comprehensively.

According to the VynZ Research, the Global Newborn Screening Market size is sub-divided into multiple segments and each segment-wise analysis provides details regarding reasons behind the segment-wise expansion, CAGR, volume, revenue, production, consumption, sales, manufacturing cost, pricing, factors affecting the geographical growth rate.

Get a sample copy of the market analysis report: https://www.vynzresearch.com/healthcare/global-newborn-screening-market/request-sample

The list of major key players of the Global Newborn Screening Market is mentioned in "Competitive insight" along with a thorough overview of their strategies and contribution to the growth plan. Additionally, it provides details on the advantages and disadvantages, institutional growth, cutting-edge discoveries, mergers and acquisitions, expansion plans, footprint, market presence, and product portfolios of the key rivals in the market. Some of the leading market players covered in this global market report are: -

PerkinElmer

Demant A/S

Natus Medical

Bio-Rad Laboratories

Danaher Corporation

Medtronic

Chromsystems Instruments & Chemicals GmbH

Trivitron Healthcare

Baebies

Recipe Chemicals+Instruments

Market segment

This report bifurcates the global market into following categories: -

By Test

Robotic Systems

Services

By Technology

Inspection and Measurement

Object Reconstruction

Projection and Navigation

Reporting and Virtualization

Others

Reason to buy this report

This research report is unbiased and gives the deep insight of market statistics including information on the main market trend and the projected size of the worldwide market based on regional and competitive analyses. The growth of the market has been aided by a number of variables, which are also discussed in this market research report. The report also covers the most innovative and effective techniques for gathering, compiling, estimating, and analyzing market data.

Explore more reports by VynZ Research

Global Wound Dressing Market – Analysis and Forecast (2021-2027)

Global Smart Home Healthcare Market – Analysis and Forecast (2021-2027)

Global Pulse Oximeter Market - Analysis and Forecast (2021-2027)

Global Beauty Devices Market – Analysis and Forecast (2022-2030)

[megasddw-blog]

Global Cystic Fibrosis Market 2019 Trends and Competitive Landscape Outlook -2023

MRFR Provides Appropriate Analysis of Global Wound Care Market by Geographical Analysis, Scope, Applications, Products, Prominent Audience, End Users, and Market Players for Global, and Country Level Market Segments, etc

Cystic fibrosis is a genetic disorder that commonly affects the lungs and also the other secretory glands such as pancreas, liver, kidneys and intestine. As per the report that has been published by Market Research future (MRFR), the global cystic fibrosis market is anticipated to expand significantly at a CAGR of 13.5% during the forecast period of 2016-2022.

The incidences of diseases caused due to genetic disorders owing to mutation in human genes are increasing rapidly. The prevalence of such diseases is generating high demand for effective treatments. Increased research and development activities in order to introduce new drugs and highly effective treatments for cystic fibrosis owing to the high prevalence of this disease is leading to the significant growth of the global cystic fibrosis market.

Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/1825

Development of various diagnostic tests to detect genetically inherited cystic fibrosis and high investment in R&D are projecting positive impact on the expansion of the global cystic fibrosis market. Initiatives such as newborn screening programs to diagnose cystic fibrosis at young age and introduction of new drugs with higher efficacy are fueling the growth of the global cystic fibrosis market.

However, increase in the complexity of disease and high cost of treatment along with lack of awareness are likely to impact negatively on the growth of the global cystic fibrosis market during the forecast period.

Competitive Analysis:

Leading players in the global cystic fibrosis market include Vertex Pharmaceuticals, AbbVie, Novartis, Pharmaxis, Forest Laboratories, Chiesi Farmaceutici, Genentech, Gilead Sciences, and F. Hoffman-La Roche.

Industry Updates:

In 2019, the U.K. NHS presented an offer to Vertex for its cystic fibrosis drug Orkambi. The first offer of more than GBP 500 million was rejected by Vertex, with more talks planned in March 2019.

Segmentation:

On the basis of treatment method, the global cystic fibrosis market is segmented into medication, devices, and other treatments.

The medication treatment segment accounted for a dominant 76.4% of the global cystic fibrosis market in 2016 and is likely to exhibit the highest 14% CAGR over the forecast period. Despite the high share of the medication segment, the global cystic fibrosis market’s growth prospects are hindered by the high costs of the medication available in the market, as this prices out several consumer demographics, particularly in emerging, high-volume markets such as Asia Pacific.

Industry Updates:

In August 2018, an independent advisory committee by the Federal government has announced that a new drug, Orkambi, will soon be subsidized and listed on the Pharmaceutical Benefits Scheme and will be made available for public use.

Regional Analysis:

The global cystic fibrosis market is segmented by region into North America, Europe, Asia Pacific, and the Middle East and Africa.

North America is likely to remain the major regional segment of the global cystic fibrosis market over the forecast period due to the growing medical research sector in the region. The strong presence of the CFF in North America as well as the growing interest in cystic fibrosis research in the region are likely to be the major drivers for the cystic fibrosis market in North America over the forecast period. The North America cystic fibrosis market is expected to reach a value of USD 521 million by 2022. Cystic fibrosis is a relatively rare disease, with around 70,000 people estimated to be suffering from it in 2017. The CFF has played a vital role in the development of the global cystic fibrosis market, as before the initiation of the foundation, research into cystic fibrosis was severely lacking. In 2018, the CFF provided USD 100 million to the Infection Research Initiative, along with funding research into other aspects of cystic fibrosis, such as the inflammation and gastrointestinal problems associated with the disease.

Europe is expected to exhibit the fastest growth in the global cystic fibrosis market, growing at a robust 14.1% CAGR over the forecast period. Europe and North America hold comparable shares in the global cystic fibrosis market and are likely to remain the leading regional parties over the forecast period.

Browse Complete 85 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

[the-rachana]

Digital Genome Market Is Thriving Worldwide – BioMérieux, Inscripta Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd.

The scientific community has tried to address genetic susceptibility and severity to SARS-CoV-2 infection by combining research efforts using existing genetic databases. Multiomic-based approaches and genome-wide association studies (GWAS) have been employed to uncover biological networks and common variants underlying host-pathogen interactions. Similarly, data derived from genomes, such as polygenic risk scores (PRS), ABO blood groups, and HLA haplotypes, can be potentially used to decipher COVID-19 complications, resistance, and susceptibility.

The global Digital Genome market reached ~US$ 12.1 billion in 2021. The market is expected to witness a CAGR of 10% from 2022 to 2030.

Prenatal genetic screening programs are likely to grow at a significant pace. This is because these programs help expectant mothers identify chromosomal anomalies in their offspring. Moreover, it is anticipated that in the next 10 years, every newborn’s genome would be sequenced and stored in the electronic medical record. Gauging the future market potential of genomics in newborn screening programs, emerging companies like Counsyl and Natera have launched various genetic tests to maintain their competitive edge in the market.

Get a Sample PDF of the Report - https://growthplusreports.com/inquiry/request-sample/digital-genome-market/7910

Key Players

·         BioMérieux

·         GenMark Diagnostics, Inc.

·         Illumina, Inc.

·         Thermo Fisher Scientific

·         NanoString Technologies, Inc.

·         Inscripta Inc.

·         GE Healthcare Genomic Health, Inc.

·         Pacific Bioscience, PerkinElmer Inc.

·         Qiagen Quest Diagnostics

·         Agilent Technologies Inc.

·         Becton, Dickinson and Company

·         F. Hoffmann-La Roche Ltd.

·         Regeneron Pharmaceuticals, Inc.

  By Product Type  

·         Sequence & Analysers Instruments

·         DNA/RNA Analysis kits

·         Sequencing & Analysis Software

·         Sample Preparation Instrument

By Application

·         Microbiology

·         Reproductive & Genetic

·         Transplant & Agriculture

·         Forensics

·         Research & Development

Key Reasons to Purchase:

(1)   To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

(2)   Assess the production processes, major issues, and solutions to mitigate the development risk.

(3)   To understand the most affecting driving and restraining forces in the Digital Genome Market and its impact in the global market.

(4)   Learn about the market strategies that are being adopted by leading respective organizations.

(5)   To understand the outlook and prospects for the market.

Key Questions Answered in the Report Include:

(1)   This report gives all the information about the industry analysis, revenue, and overview, of this market.

(2)   What will be the rate of increase in market size and growth rate by the end of the forecast period?

(3)   What are the major global Digital Genome Market trends influencing the development of the market?

(4)   What are the vital results of SWOT analysis of the major players operating in the Digital Genome Market?

(5)   What are the potential growth opportunities and threats faced by Major competitors in the market?

TOC of Digital Genome Market

1 Scope of the Report

1.1 Market Ecosystem

1.2 Geographic Scope

1.3 Timeline Under Consideration

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Digital Genome Market Executive Summary

2.1 World Market Overview

2.1.1 Global Market Size 2022-2030

2.1.2 Market Size CAGR by Region 2020 VS 2028

2.2 Digital Genome Market Segment by Type

2.2.1 Type 1

2.2.2 Type 2

Browse the full report now: https://growthplusreports.com/report/digital-genome-market/7910

About us

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

[rahulmmr]

Newborn Screening Market Segments by Region, Growth, Price, Sales and Revenues of Manufacturers Forecast till 2027

Newborn Screening Market   is expected to grow at a CAGR of 8.3% during the forecast period. Global Newborn Screening Market is expected to reach US$ 1.78 Bn. by 2027.

Newborn Screening Market Overview:

The Maximize Market Research Report investigates a number of factors that support market expansion. The report covers market trends, openings, obstacles, and elements that either favour or hinder the market. The numerous industries and applications that may have an impact on the market throughout the projected period are also covered in this section. This data is based on both recent and historical trends. A summary of global and type-specific output from 2022 to 2029 is also provided in this section. The regional production from 2022 to 2029 is discussed in this section. Prices range from 2022 to 2029 for each type, 2022 to 2029 for the region, and 2022 to 2029 for the entire world.

Market Scope:

The Newborn Screening market is anticipated to develop at the fastest rate from 2022 to 2029. Trends in supply and demand are examined in the Maximize Market Research (MMR) report together with costs, prices, shares, volumes, sales, and gross profits. The manufacturing unit, capacity, production, factory price, market price, and market share of each firm are examined in this MMR data collection.

Request Sample: https://www.maximizemarketresearch.com/request-sample/21865 

Segmentation:

by Test Type

• Hearing screen test • Critical congenital heart disease Test • Dry blood spot test

by Technology

• Hearing screen technology • Electrophoresis • Tandem Mass Spectrometry • Pulse Oximetry Technology • DNA based assays • Enzymes & Immunoassay

Key Players:

• AB Sciex • Agilent Technologies Inc • Bio-Rad Laboratories Inc • Covidien PLC • GE Healthcare • Masimo Corporation • Medtronic Inc • Natus Medical Incorporated • PerkinElmer Inc • Trivitron Healthcare • Waters Corporation • ZenTech S.A

Regional Analysis:

The MMR report covers all of North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. MMR takes into account important market segments and sub-segments as well as important market sectors in this study. The MMR survey rates creative nations in local development based on market size, percentage, and volume. Volume, area, sales, market chain systems, and trends are just a few examples of numbers.

COVID-19 Impact Analysis on Newborn Screening Market:

The COVID-19 Regulation has a significant impact on the aspirations of society, business, and labour between 2020 and 2021. COVID-19 requires quick industry assistance and invention since it has the ability to destroy our civilization and way of life. For migrant labourers in India, COVID-19 has created numerous issues. Millions of migrant workers have lost their employment, experienced food shortages, and worried about their future prospects as a result of the country's embargo.

This MMR study's main objective is to gain a better understanding of the modern economy, COVID-19, and its economic implications. MMR is keeping track of COVID-19 in all fields, divisions, and specialties. Similar information can be found in the Maximize Market Research Report, which may be used to analyse how COVID-19 has affected industry losses and growth.

Key Questions answered in the Newborn Screening Market Report are:

Which product segment grabbed the largest share in the Newborn Screening market? How is the competitive scenario of the Newborn Screening market? Which are the key factors aiding the Newborn Screening market growth? Which region holds the maximum share in the Newborn Screening market? What will be the CAGR of the Newborn Screening market during the forecast period? Which application segment emerged as the leading segment in the Newborn Screening market? Which are the prominent players in the Newborn Screening market? What key trends are likely to emerge in the Newborn Screening market in the forecast period? What is the expected Newborn Screening market size by 2029? Which company held the largest share in the Newborn Screening market?

[soumyafwr]

https://www.xaphyr.com/blogs/569681/Newborn-Screening-Market-Analysis-Size-Share-and-Forecast-2031

Newborn Screening Market Analysis, Size, Share, and Forecast 2031

[insightfulblogz]

Bilirubin Blood Test Market Segmentation, CAGR Status, Leading Trends, Forecast to 2032

The bilirubin blood test is a crucial diagnostic tool used to assess liver function and overall health. Bilirubin is a yellow compound produced during the breakdown of red blood cells and is processed by the liver. Elevated levels of bilirubin in the bloodstream can indicate liver disease, bile duct obstructions, hemolysis, or other underlying medical conditions. This simple blood test provides valuable information about a patient’s metabolic and hepatic status, making it an essential component of routine medical evaluations. The increasing prevalence of liver-related disorders, combined with a growing emphasis on preventive healthcare, has led to heightened awareness and utilization of the bilirubin blood test in clinical practice.

The Bilirubin Blood Test Market Size was valued at USD 1.18 billion in 2023, and is expected to reach USD 2.11 billion by 2032, and grow at a CAGR of 6.7% over the forecast period 2024-2032.

Future Scope

The future of the bilirubin blood test is poised for innovation, particularly with advancements in point-of-care testing and telemedicine. The development of portable and non-invasive bilirubin measurement devices may enhance accessibility and convenience, allowing for real-time monitoring of bilirubin levels in various settings. Additionally, integrating artificial intelligence (AI) into diagnostic processes can improve the interpretation of bilirubin results, enabling healthcare providers to make more informed decisions regarding patient management. As research continues to uncover the complexities of liver health, bilirubin testing may expand to include new biomarkers that provide a more comprehensive understanding of liver function and disease progression.

Trends

Recent trends in bilirubin testing reflect an increasing focus on early detection and preventive health measures. Routine screenings for liver function, including bilirubin tests, are becoming more common in annual health check-ups, particularly for high-risk populations such as individuals with a history of alcohol use, obesity, or viral hepatitis. Furthermore, the rise of consumer health technology has led to the emergence of home testing kits that allow individuals to monitor their bilirubin levels and liver health at home. This shift toward proactive health management underscores the importance of awareness and education regarding liver disease and its potential consequences.

Applications

The bilirubin blood test is primarily used to evaluate liver function and diagnose conditions such as jaundice, liver cirrhosis, and hemolytic anemia. Healthcare providers often use bilirubin levels in conjunction with other liver function tests to obtain a comprehensive picture of a patient’s hepatic health. The test is also valuable in monitoring patients with known liver conditions to assess disease progression and response to treatment. Moreover, bilirubin testing can play a role in newborn care, as elevated bilirubin levels in infants may indicate physiological or pathological jaundice that requires medical intervention.

Key Points

The bilirubin blood test is vital for assessing liver function and diagnosing various medical conditions.

Elevated bilirubin levels can indicate liver disease, bile duct obstruction, or hemolysis.

The future of bilirubin testing includes innovations in point-of-care devices and AI integration.

Routine screenings for bilirubin levels are becoming more common in preventive healthcare.

Home testing kits for bilirubin monitoring are emerging as a convenient option for consumers.

Conclusion

The bilirubin blood test is an essential diagnostic tool in modern medicine, providing critical insights into liver health and overall well-being. As advancements in technology and a growing emphasis on preventive care shape the future of healthcare, the role of bilirubin testing will continue to evolve. By prioritizing liver health and raising awareness of the importance of early detection, healthcare providers can significantly improve patient outcomes and contribute to a healthier population.

Read More Details: https://www.snsinsider.com/reports/bilirubin-blood-test-market-3245 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[shreyas-inkwood]

Genetic Testing Market Growth & Trends | Analysis by 2030

Genetic testing is one of the rapidly evolving segments in the healthcare sector. It is estimated that the global genetic testing market will evolve at 10.25% of the CAGR between 2022 and 2030. The increasing incidence of genetic diseases and the rising applications build the groundwork for the market’s opportunistic progression.

Genetic testing helps identify changes in proteins, chromosomes, or genes. The results can rule out or confirm a suspected genetic condition and determine the chances of passing or developing a genetic disorder.

The top trend-setting factors in the market are the rise in the aging population and technological advancements. As per the United Nations’ World Population Prospects 2020 Highlights, more than 1.5 billion will be aged over 65 by 2050. The aging population is vulnerable to chronic diseases, thereby raising the demand for preventive diagnostics, especially genetic testing. Further, the growing cases of inherited diseases like hemophilia, cystic fibrosis, and sickle cell anemia are pushing the need for genetic testing.

Genetic Testing Market by Segmentation | Trends 2022

The global genetic market report scope includes the segmentation analysis of disease, application, technology, and type. The government initiatives in terms of genetic testing awareness, the rising disposable income, and technological advancements facilitate the growth of key segments like type and disease. For instance, genetic testing is increasingly being used in pharmacogenomics, also called drug-gene testing. This is also attributed to the genetic testing techniques advancements.

The cancer segment is expected to have the largest revenue share in the global genetic testing market by disease.

Cancer is the second-leading cause of death, with almost 70% of deaths occurring in low-and-middle-income countries. Genetic testing aids in estimating the chances of developing cancer by assessing the specific changes in genes, chromosomes, and proteins. This leads to increased surviving probability, cost-effective treatment, and minimal morbidity.

The increasing awareness about personalized medicine and preventive diagnosis, and the growing cancer burden, contribute to the segment growth. According to the International Agency for Research on Cancer (IARC), the new cancer incidence is predicted to reach 30.2 million by 2040.

Furthermore, the growing technological advancements and product launches boost the cancer segment’s growth. For instance, Roche launched the Cobas PIK3CA Mutation Test in December 2020 for detecting PIK3CA mutations in advanced or metastatic breast cancer patients.

Moreover, the rising popularity of direct-to-consumer channels, the growing adoption of self-testing kits, increased consumer expenditure on healthcare, and easy access to genetic testing services boost growth opportunities in the type segment.

The prenatal & newborn testing segment is evaluated to be the fastest-growing test type.

This is accredited to surging demand to identify health complications in newborn or prenatal babies, particularly in developed countries. Also, prenatal screening helps identify several health conditions like Down syndrome, Edward syndrome, and patau syndrome. Further, as per the Centers for Disease Control and Prevention, the perinatal mortality was stable, with stillbirth affecting almost 1% of all pregnancies in the US in 2012.

In addition, extensive research associated with genomics and proteomics and heavy investments in research activities has resulted in substantial technological advancements.

Asia-Pacific is expected to project more growth opportunities given the increased government initiatives, the rising research activities, large population, awareness of early screening of genetic disorders, growing medical tourism, and increasing demand for quality healthcare. Whereas North America is estimated to fare more in terms of revenue share due to the presence of key players like  23andMe, Myriad Genetics Inc, PerkinElmer Inc, Illumina Inc, etc., a strong base of healthcare facilities, and a surging pregnancy rate.

Future Potential

Some aspects of most diseases are influenced by changes in the patient’s genome. In this regard, there is immense potential for genetic testing in promising applications like tumor molecular profiling like liquid biopsies to select cancer treatment, sequencing for rare diseases, and non-invasive prenatal diagnostics. Additionally, the increasing acceptance and accessibility of non-targeted sequencing among consumers and patients are evaluated to offer growth opportunities for the global genetic testing market.

[technologyreportsworld]

Newborn Screening Market Analysis, Top Key Players, and Industry Statistics, 2021-2028

The report discusses in detail the growth opportunities, challenges, market drivers and restraints, limitations, threats, and demands of the Newborn Screening Market  . The study further assesses the regional market as well as the international market to garner an insight into the scope of the market. The report also offers estimations and predictions about the market segment and sub-segments exhibiting promising growth in the forecast timeline. The report also provides deeper insights into the technological advancements, industrial landscape, and emerging product and technological developments in the Newborn Screening market. It offers fruitful insights into the business sphere to help businesses capitalize on the lucrative growth opportunities.

Keyplayer :

Bio-Rad Laboratories Inc., Agilent Technologies Inc., Trivitron Healthcare, Natus Medical Inc., PerkinElmer Inc., AB Sciex LLC, Covidien Plc, Masimo Corp., GE Healthcare, and Waters Corp., among others.

Get a sample of the report : https://www.emergenresearch.com/request-sample/4

The report further assesses the Newborn Screening market dynamics, market landscape, company profiles, production and manufacturing capacity, year-on-year growth rate, SWOT analysis, and Porter’s Five Forces analysis. It offers in-depth assessment of key companies operating in the market on the basis of their expansion plans, market position, financial standing, and gross profit margins. It also provides information about their current advancements and key market strategies. Furthermore, the report provides a comprehensive overview of the Newborn Screening market along with product portfolio and market performance.

Segmentation :

For the purpose of this report, Emergen Research has segmented the global Newborn Screening Market on the basis of Technology, Product, Application, and region:

Technology Outlook (Revenue, USD Billion; 2017-2027)Tandem Mass Spectrometry Pulse Oximetry Enzyme Based Assay DNA Assay Electrophoresis Others

Product Outlook (Revenue, USD Billion; 2017-2027)Instruments Reagents Assay Kits Others

Application Outlook (Revenue, USD Billion; 2017-2027)Dry Blood Spot Test Critical Congenital Heart Disease (CCHD) Hearing Screen Others

Read More Detail About Newborn Screening Market Report : https://www.emergenresearch.com/industry-report/new-born-screening-market

Key Questions Answered in the Report:

What is the growth rate of the Newborn Screening market? What is the anticipated market valuation of Newborn Screening industry by 2027?

What are the key growth driving and restraining factors of the Newborn Screening market?

Who are the prominent players operating in the market? What are the key strategies adopted by these companies?

What are the key opportunities and growth prospects of the Newborn Screening industry over the forecast period?

Which region is expected to show significant growth in the coming years?

Key points discussed in the report for Global Newborn Screening Market:

Chapter 1: Introduction, market driving force product, Objectives of the Study, and Research Scope of the Newborn Screening market

Chapter 2: Exclusive Summary –vital information of the Newborn Screening Market.

Chapter 3: Market Dynamics- Drivers, Trends, and Challenges of the Newborn Screening Market

Chapter 4: Newborn Screening Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Market segmentation by Type, End-User and Region 2016-2018

Chapter 6: Analysis of the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 7 & 8: Appendix, Methodology and Data Source…Continued

Finally, Newborn Screening Market is a valuable source of guidance for individuals and companies.

Request a discount on the report : https://www.emergenresearch.com/request-discount/4

Key geographical areas:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Thank you for reading our report. Customization of this report is available in chapter-wise or region-wise sections. Kindly get in touch with us to know more about the report, and our team will provide excellent assistance.

More reports by emergen research @

Waterproofing Systems @ https://www.emergenresearch.com/industry-report/waterproofing-systems-market

Solar LED Street Lighting @ https://www.emergenresearch.com/industry-report/solar-led-street-lighting-market

3D Printing Metal@@ https://www.emergenresearch.com/industry-report/3d-printing-metal-market

Operating Room Integration Systems@  https://www.emergenresearch.com/industry-report/operating-room-integration-systems-market

Small Caliber Ammunition@ https://www.emergenresearch.com/industry-report/small-caliber-ammunition-market

Micro Displays@ https://www.emergenresearch.com/industry-report/micro-displays-market

About Us: At Emergen Research, we believe in advancing with technology. We are a growing market research         and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkdIn | Twitter | Blogs

[reallyzealousnight]

Clinical Genomics Market Analysis 2021

Clinical Genomics: Introduction

·         A genome is a complete set of DNA contained in a single cell of an organism. Genomics is a branch of genetics that studies the sequencing and interpretation of a living organism's genome. Clinical genomics is the analysis of an organism's genetic make-up for diagnostic reasons such as cancer prognosis or diagnosis, determining pre-existing causes of a potential disease, and tailoring care regimens to the needs of a patient. Advancement in molecular biology has revolutionized cancer detection and treatment. Modern disease detection techniques focused on the detection of DNA and RNA have several benefits over conventional methods.

 𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧, 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝑭𝒓𝒆𝒆 𝐏𝐃𝐅 𝐇𝐞𝐫𝐞➦https://www.meticulousresearch.com/download-sample-report/cp_id=3763

 Key Drivers and Restraints of Global Clinical Genomics Market

·         Continuous innovation in clinical genomics to be major driver

o    Clinical genomics innovation has resulted in improved health services and improved treatment options for patients. Genetic screening offers various tools for the detection of genetic diseases, including RT-PCR, microarray sequencing, and next-generation sequencing. Availability of various technologies for disease detection provides several options, depending on the cost of the examination, its capability, and other factors. This is projected to fuel the growth of the global clinical genomics market during the forecast period. Comparative genomic hybridization (CGH), also known as chromosomal microarray analysis (CMA), is a technique for identifying copy number variations.

o    CGH is considered a new technology that can be used to identify chromosomal abnormalities as well as solid tumors. Due to advances in workflow and cost efficiency, array comparative genomic hybridization (aCGH) is quickly becoming the preferred CGH technique over other conventional techniques. The technology is expected to replace current conventional banding techniques, which in turn is anticipated to propel the global clinical genomics market. According to the World Health Organization (WHO), cancer accounts for 8.3 million deaths globally each year, with 70% of new cancer cases projected to be identified in the next 20 years.

o    Each type of cancer requires a different approach to treatment. Hence, demand for clinical genomics is expected to increase during the forecast period, driven by rise in prevalence of cancer and the need for personalized medicine. The clinical genomics industry is still in a nascent stage. This is likely to provide significant opportunities to market players.

Check Discount Here :-https://www.meticulousresearch.com/requestdiscount/cp_id=3763

Scope of the Report:

Clinical Genomics Market by Test Type:

Diagnostic Testing

Genetic Testing

Newborn Screening

Preimplantation     Testing

Prenatal Testing

Carrier Testing

Other Tests

Clinical Genomics Market by Method:

Molecular Tests

Chromosomal Tests

Biochemical Tests

Clinical Genomics Market by End User:

Hospitals &     Clinics

Government     Laboratories & Research Centres

Academics and     Research Institutes

Other End Users

Clinical Genomics Market by Geography:

 U.S.

 Canada

Key questions answered in the report:

Adoption of test over software will propel the clinical genomics market

How does the     prenatal testing increase the efficiency and adoption of clinical genomic     tests?

How are the leading     players utilizing the advantages of prenatal testing in their products?

Which are the high     growth market segments in terms of service, method, end users, and     geography?

Hospitals & clinics end user accounted for the largest share of the clinical genomics market

What factors are    contributing to the frequent usage of tests in the hospital and clinics?

How does the     penetration of clinical genomics tests in hospital and clinics differ from     other end users?

The Asia-Pacific clinical genomics market favors both larger and local manufacturers that compete in multiple segments

What are the top     competitors in this market and what strategies do they employ to gain     shares?

What factors are     driving growth and which market segments have the most potential for     revenue expansion over the forecast period?

What strategies     should new companies look to enter this market use to compete effectively?

What are the major  drivers, challenges, opportunities, and trends in the global clinical   genomics market?

Who are the major   players in various countries and what share of the market do they hold?

What are the geographical trends and high growth regions/countries?

𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧, 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 (Pages 194)𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞➦https://www.meticulousresearch.com/Checkout/32408125

About Us:

intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Through our mixed bag of research offerings – syndicated research, custom research, and analyst engagement — we enable smart decision making to enhance business performance for global organizations. Our focus is also on finding answers to the challenging questions that global business leaders face on a daily basis. Each year, we deliver more than 300 syndicate studies and 60+ consulting projects across eight industry verticals in 20+ geographic markets.

[chitrakullkarni]

DNA Testing/Diagnostics Market Prominent Players, Recent Developments and Trend Analysis

The global DNA Testing/Diagnostics Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.

Market Overview:

The global DNA Testing/Diagnostics Market is anticipated to grow at a staggering CAGR in the forthcoming period. Diagnostic tests are the basis of a successful healthcare system that enables vital information about patients and healthcare providers necessary to land into right decisions.

Key Players:

454 Life Sciences

Abbott Laboratories

Affymetrix Inc.

Agilent Technologies Inc.

Applied Biosystems Group

Thermo Fisher Scientific Inc.

Illumina

Cepheid

Hologic

Bio-Rad Laboratories

Dako

Alere

Roche Diagnostics

Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/dna-testing-diagnostics-market/request-sample

Growth Drivers:

The drivers for DNA testing market include demand for personalized medicine applications for chronic disorders is likely to propel the market growth. Rise in demand for DNA diagnostics for new born babies adds to the market growth during the forecast period. In addition, genetic testing gains a higher traction to determine patient’s health at different stages of disease development fuels the market growth.

Technology Outlook:

Microarrays based diagnostics

PCR based diagnostics

In-situ hybridization diagnostics

NGS DNA diagnosis

Application Outlook:

Prenatal DNA Carrier Screening

Preimplantation Diagnosis

Newborn Genetic Screening

Infectious Disease DiagnosticsHBV Diagnostic HCV Diagnostic HIV Diagnostic TB Diagnostic CT/NG Diagnostic HPV Diagnostic MRSA Diagnostic

Oncology Diagnostics & Histopathology

Identity Diagnostics & Forensics

Pharmacogenomics Diagnostic Testing

Drug Metabolism & P450 effects

Regional Outlook:

Myogenic disorder is further segmented as pre-implantation diagnostics and prenatal diagnostics. Geographical segmentation for DNA testing market includes North America, South America, Europe, Asia-Pacific, Middle East and Africa. North America holds a dominant share in the global market owing to rise in adoption of DNA diagnostics technology and significant prevalence of chronic and infectious disease.

Asia-Pacific market is anticipated to rise at a higher CAGR due to rise in research programs conducted by government in developing economies. Constant R&D and commercialization of technology for treatment of chronic diseases is likely to contribute to the market growth during the forecast period. The key players in the DNA diagnostics industry include Cephide Inc., 454 Life Sciences, Abbott Laboratories, Beckman Coulter Inc., Bio-Rad Laboratories, Hologic, GE Healthcare, Thermo Fisher Scientific, Illumina Inc., TransgenomicInc., Siemens Healthcare, Roche Diagnostics, Qiagen, Illumina, AlereInc, Affymetrix Inc., Agilent Technologies Inc., Dako, and Applied Biosystems Group.

Browse Related Category Research Reports @ https://industryanalysisandnews.wordpress.com/

[marketresearchtrendsblog]

Hemophilia Market – Analysis, Share, Trends, Size, & Forecast From 2020 – 2027

The hemophilia market is estimated to represent a global market of USD 11.62 billion by 2019 with growth rate of 5.3%.

Market Dynamics

Over the eight years to 2016, revenue for the hemophilia industry is anticipated trend higher. Increasing neonatal population is expected to drive the hemophilia diagnosis demand globally. The World Population Meter stated that more than 88.0 billion newborns were reported in 2015 resulting in about 250 births per minute. Of which, approximately 2.8 million infants died within the first month, due to lack of skilled care and proper screening of the babies. The World Health Organization (WHO) also stated that around 2.6 million children died in their first month of life across the globe, which is 7,000 newborn deaths every day. In addition, strong product pipeline will further stimulate the industry growth to great extent over the future period. For example, N9-GP, Concizumab, N8-GP, and Recombinant factor VIIa are some of the bleeding disorder therapeutics under clinical investigations by Novo Nordisk. Despite the industry pipeline increasing, some potential threats exist which will likely to hinder growth prospects going forward. Factors such as high treatment cost coupled with low acceptance of advanced technologies are posing a potential threat to the market. Types Takeaway In terms of types, the market is categorized into A, B, C, and other types. Type A accounted for the highest share of the total market. In 2019, the segment recorded 6.8 billion and is expected to dominate the global market over the forecast period. This type is acquired due to the deficiency of clotting factor VIII, which is an anti-hemophilic factor (AHF). According to the National Hemophilia Foundation (NHF), 1 in 5,000 male population affect with type A disorder, which makes it four times more common compared to the type B. As per the Hemophilia News Today, around 4,000 to 5,000 males are affected with type A disease worldwide. Markets besides hemophilia A, B & C is expected to generate the remaining 5.0% of market revenue in 2019. COVID 19 Impact on hemophilia market As key companies move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on strategies that may result in emerging as strong market player. The published research included the detailed study related to the COVID-19 Impact on the supply chain based on both downstream and upstream markets. The proposed report also includes the future development in the hemophilia Market in relation with the impact of COVID-19 on the market.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-53288

Key Vendor Takeaway

Companies namely, Novo Nordisk, Bayer AG, Pfizer, Inc., Baxalta, and Biogen are profiled. In light of more players entering in this market. the degree of competition has intensified over a couple of years. Competition is based on the development of new therapeutics and co-pay programs. For example, Grifols provide co-pay programs such as ALPHANATE Copay Program and AlphaNine SD Copay card for this bleeding disorder treatment with an unlimited monetary limit. In addition, companies are engaged in donation activities with government organizations. For instance, in 2016, the World Federation of Hemophilia collected 1.5 million units of anti-hemophilic agents from CSL Behring as a donation on World Hemophilia Day. The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment. The years considered for the study are: Historical Year – 2016 to 2018 Base Year – 2019 Estimated Year – 2020 Projected Year – 2027 The proposed reports analyse and evaluates the COVID-19 Impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows: HEMOPHILIA MARKET, BY TYPES Hemophilia A Hemophilia B Hemophilia C Others HEMOPHILIA MARKET, BY TREATMENT On-demand Prophylaxis HEMOPHILIA MARKET, BY THERAPY Immune Tolerance Induction (ITI) therapy Replacement therapy Gene therapy HEMOPHILIA MARKET, BY REGION North America U.S. Canada Europe Germany France Rest of Europe Asia Pacific India China Rest of APAC Rest of the World Middle East and Africa Latin America

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count Email: sales@sdki.jp Tel: + 81 3 45720790